Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Increases By 20.5%

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of a large increase in short interest in February. As of February 27th, there was short interest totaling 2,971,195 shares, an increase of 20.5% from the February 12th total of 2,466,525 shares. Approximately 16.4% of the company’s stock are sold short. Based on an average daily volume of 516,202 shares, the short-interest ratio is presently 5.8 days. Based on an average daily volume of 516,202 shares, the short-interest ratio is presently 5.8 days. Approximately 16.4% of the company’s stock are sold short.

Karyopharm Therapeutics Trading Down 2.0%

NASDAQ KPTI traded down $0.17 during trading hours on Tuesday, hitting $8.38. 702,459 shares of the company’s stock traded hands, compared to its average volume of 609,852. Karyopharm Therapeutics has a 52 week low of $3.51 and a 52 week high of $10.99. The firm has a market capitalization of $153.72 million, a P/E ratio of -0.50 and a beta of 0.13. The business’s fifty day moving average price is $7.88 and its two-hundred day moving average price is $6.83.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.03. The business had revenue of $34.08 million for the quarter, compared to analysts’ expectations of $33.16 million. On average, sell-side analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KPTI. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a report on Tuesday, March 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. Cantor Fitzgerald started coverage on shares of Karyopharm Therapeutics in a report on Thursday, February 5th. They set an “overweight” rating on the stock. Finally, The Goldman Sachs Group set a $12.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.71.

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of KPTI. Corient Private Wealth LLC bought a new position in shares of Karyopharm Therapeutics in the fourth quarter worth about $74,000. Baird Financial Group Inc. bought a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at approximately $45,000. Tudor Investment Corp ET AL purchased a new stake in Karyopharm Therapeutics in the 4th quarter worth approximately $95,000. XTX Topco Ltd purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth approximately $56,000. Finally, Persistent Asset Partners Ltd bought a new stake in Karyopharm Therapeutics during the 4th quarter worth approximately $135,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.